Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer

项目 2:HPV 阴性头颈癌的合成致死疗法

基本信息

  • 批准号:
    10267848
  • 负责人:
  • 金额:
    $ 51.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-22 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Summary HPV-negative head and neck squamous cell carcinomas (HNSCC) typically lose G1/S cell cycle checkpoints, with most tumors having mutations in TP53, and many also mutating other tumor suppressors such as CDKN2A. Such tumors become dependent on checkpoints associated with G2/M to repair DNA damage arising from replication stress and other genomic insults. This dependency suggests a tumor-selective vulnerability to synthetic lethal strategies controlling progress through G2/M. In extensive preliminary data, we show that AZD1775/adavosertib, an inhibitor of the G2/M checkpoint kinase WEE1, potently sensitizes TP53mut HNSCC cell lines to inhibition of Aurora A kinase (AURKA). WEE1 induces an inhibitory Y15-phosphorylation of CDK1, blocking M-phase entry and thus blunting the cytotoxic effects AURKA inhibition. WEE1 inhibition abrogates this arrest, accelerating mitotic entry for cells bearing highly disruptive spindle abnormalities and other defects arising from AURKA inhibition, resulting in mitotic catastrophe and apoptosis. We found combined AURKA/WEE1 inhibition is potent in HNSCC xenografts, while well-tolerated in normal tissue and cells. We have extended this concept, identifying additional promising drug combinations between WEE1 and other G2/M regulatory kinases (PLK1 and CHK1). Notably, the limited number of cells surviving synthetic lethal treatment are characterized by aneuploidy and other defects suggesting they may have increased tumor mutation burden (TMB), express neoantigens, and upregulated inflammatory signaling associated with sensitivity to immune checkpoint inhibition. This project will take this observation directly to the clinic. We will conduct a pre-operative window phase I and expansion clinical trial of the late generation, high potency selective AURKA inhibitor LY3295668 with adavosertib combination, establishing pharmacodynamic proof of concept, identifying biomarkers for patient selection in future studies, and placing synergistic combinations in context of genomic alteration and treatment resistance. In Aim 1, we will evaluate mechanisms of combination lethality, and use single cell sequencing and Luminex profiling to query TMB, predict neoantigens, and measure inflammatory signaling. Aim 2 will query the effect of classes of common HNSCC TP53 and CDKN2A mutations, and cisplatin resistance, on response to a WEE1-AURKA inhibitor combination, using defined cell line models and patient derived xenografts (PDXs). In Aim 3, we will perform a pre-operative window trial to establish recommended phase 2 doses, determine activity and establish pharmacodynamic proof of concept, and to evaluate putative predictive biomarkers for response to combination WEE1/AURKA inhibition in HNSCC.
总结 HPV阴性头颈部鳞状细胞癌(HNSCC)通常失去G1/S细胞周期检查点, 大多数肿瘤在TP 53中具有突变,并且许多肿瘤还突变其它肿瘤抑制因子如CDKN 2A。 这些肿瘤变得依赖于与G2/M相关的检查点来修复由G2/M引起的DNA损伤。 复制应激和其他基因组损伤。这种依赖性表明肿瘤选择性易受 通过G2/M控制进展的合成致死策略。在大量的初步数据中,我们表明, AZD 1775/adavosertib是一种G2/M检查点激酶WEE 1抑制剂,可有效致敏TP 53 mut HNSCC 细胞系抑制Aurora A激酶(AURKA)。WEE 1诱导CDK 1的抑制性Y15磷酸化, 阻断M期进入,从而减弱AURKA抑制的细胞毒性作用。WEE 1抑制消除了这一点 阻滞,加速有丝分裂进入具有高度破坏性的纺锤体异常和其他缺陷的细胞, 从AURKA抑制,导致有丝分裂灾难和凋亡。我们发现组合AURKA/WEE 1 抑制在HNSCC异种移植物中是有效的,而在正常组织和细胞中耐受良好。我们已经扩展了这个 概念,确定WEE 1和其他G2/M调节激酶之间的其他有希望的药物组合 (PLK1 CHK1)。值得注意的是,在合成致死处理中存活的有限数量的细胞的特征在于: 非整倍体和其他缺陷表明他们可能增加了肿瘤突变负荷(TMB),表达 新抗原,以及与免疫检查点抑制敏感性相关的上调炎症信号传导。 该项目将直接将观察结果带到诊所。我们将进行术前窗口期I, 新一代高效选择性AURKA抑制剂LY 3295668的扩展临床试验, adavosertib联合用药,建立药效学概念证明,确定患者的生物标志物 在未来的研究中选择,并在基因组改变和治疗的背景下放置协同组合 阻力在目标1中,我们将评估联合致死的机制,并使用单细胞测序和 Luminex分析用于查询TMB、预测新抗原和测量炎症信号传导。目标2将查询 常见的HNSCC TP 53和CDKN 2A突变类型以及顺铂耐药对化疗反应的影响 WEE 1-AURKA抑制剂组合,使用确定的细胞系模型和患者来源的异种移植物(PDX)。在 目标3,我们将进行术前窗口试验,以确定推荐的II期剂量, 并建立药效学概念证明,并评价反应的推定预测生物标志物 与HNSCC中WEE 1/AURKA联合抑制有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARBARA BURTNESS其他文献

BARBARA BURTNESS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARBARA BURTNESS', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10441505
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10668955
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
项目 2:HPV 阴性头颈癌的合成致死疗法
  • 批准号:
    10913240
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
耶鲁头颈癌孢子:克服头颈癌的治疗耐药性
  • 批准号:
    10267672
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
耶鲁头颈癌孢子:克服头颈癌的治疗耐药性
  • 批准号:
    10441504
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
项目 2:HPV 阴性头颈癌的合成致死疗法
  • 批准号:
    10668986
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
HPV 阴性头颈癌的综合致死疗法
  • 批准号:
    10838999
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10267844
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
耶鲁头颈癌孢子:克服头颈癌的治疗耐药性
  • 批准号:
    10666936
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
项目 2:HPV 阴性头颈癌的合成致死疗法
  • 批准号:
    10441510
  • 财政年份:
    2020
  • 资助金额:
    $ 51.28万
  • 项目类别:

相似海外基金

Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
  • 批准号:
    10887038
  • 财政年份:
    2023
  • 资助金额:
    $ 51.28万
  • 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
  • 批准号:
    10877239
  • 财政年份:
    2023
  • 资助金额:
    $ 51.28万
  • 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
  • 批准号:
    MR/X007979/1
  • 财政年份:
    2023
  • 资助金额:
    $ 51.28万
  • 项目类别:
    Research Grant
Cell competition, aneuploidy, and aging
细胞竞争、非整倍性和衰老
  • 批准号:
    10648670
  • 财政年份:
    2023
  • 资助金额:
    $ 51.28万
  • 项目类别:
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
  • 批准号:
    10735074
  • 财政年份:
    2023
  • 资助金额:
    $ 51.28万
  • 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
  • 批准号:
    10538074
  • 财政年份:
    2022
  • 资助金额:
    $ 51.28万
  • 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
  • 批准号:
    10537275
  • 财政年份:
    2022
  • 资助金额:
    $ 51.28万
  • 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
  • 批准号:
    10661533
  • 财政年份:
    2022
  • 资助金额:
    $ 51.28万
  • 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
  • 批准号:
    10366610
  • 财政年份:
    2022
  • 资助金额:
    $ 51.28万
  • 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
  • 批准号:
    10467260
  • 财政年份:
    2022
  • 资助金额:
    $ 51.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了